Early safety check for cenerimod in healthy people
NCT ID NCT04052360
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tested a single 4 mg dose of the drug cenerimod in 20 healthy volunteers (10 Japanese and 10 Caucasian). The goal was not to treat any disease but to see how safe the drug is and how the body absorbs and breaks it down. Participants stayed in the clinic for 4 days and had follow-up visits over about 75 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cenerimod
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults